Intravesical Ethoglucid (EpodylR) for Treatment of Noninvasive Bladder Cancer (Stage Ta)

Authors

  • Anders Larson Department of Urology, University Hospital, Uppsala, Sweden
  • Åke Fritjofsson Department of Urology, University Hospital, Uppsala, Sweden

DOI:

https://doi.org/10.3109/03009738509178649

Abstract

Widespread, well differentiated (grade I) bladder tumours confined to the mucosa (stage Ta) were treated with regular intravesical instillations of ethoglucid (EpodylR) in 24 patients. The therapeutic schedule could be followed in all but one patient, in whom side effects necessitated cessation of treatment. Complete response was obtained in 75% of the patients, and during continued prophylactic therapy 90% remained tumour-free. After termination of the treatment, however, new tumours appeared in 60–80 % of the patients.

Downloads

Download data is not yet available.

Downloads

Published

1985-06-01

How to Cite

Larson , A. ., & Fritjofsson , Åke . (1985). Intravesical Ethoglucid (Epodyl<sup>R</sup>) for Treatment of Noninvasive Bladder Cancer (Stage Ta). Upsala Journal of Medical Sciences, 90(2), 127–132. https://doi.org/10.3109/03009738509178649

Issue

Vol. 90 No. 2 (1985): Upsala J Med Sci

Section

Original Articles

License

Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.

Crossref
Scopus
Google Scholar
Europe PMC